Show simple item record

dc.contributor.authorSeaman, J
dc.contributor.authorPryce, D
dc.contributor.authorSondorp, H
dc.contributor.authorMoody, A
dc.contributor.authorBryceson, A
dc.contributor.authorDavidson, R N
dc.date.accessioned2008-04-03T14:17:56Z
dc.date.available2008-04-03T14:17:56Z
dc.date.issued1993-09
dc.identifier.citationEpidemic Visceral Leishmaniasis in Sudan: A Randomized Trial of Aminosidine Plus Sodium Stibogluconate Versus Sodium Stibogluconate Alone. 1993, 168 (3):715-20 J. Infect. Dis.en
dc.identifier.issn0022-1899
dc.identifier.pmid8394861
dc.identifier.urihttp://hdl.handle.net/10144/22252
dc.description.abstractIn a comparative trial of treatment in southern Sudan, visceral leishmaniasis was diagnosed by the following symptoms: fever for > 1 month, splenomegaly, and antileishmanial direct agglutination test (DAT) titer of > or = 1:25,600. Patients (200) were randomized to receive sodium stibogluconate (Sbv) at 20 mg/kg/day for 30 days (groups S, n = 99) or Sbv at 20 mg/kg/day plus aminosidine at 15 mg/kg/day for 17 days (group AS, n = 101). Of 192 patients who had spleens or lymph nodes aspirated at entry, 134 (70%) were positive for parasites. During treatment, 7% in group S and 4% in group AS died. All 184 patients who completed treatment were clinically cured. At days 15-17, microscopy of aspirates showed that 57 (95%) of 60 in group AS were negative for parasites compared with 47 (81%) of 58 in group S (P = .018). At day 30, 57 (93.4%) of 61 group S aspirates were negative.
dc.language.isoenen
dc.publisherPublished by Infectious Diseases Society of Americaen
dc.relation.urlhttp://www.journals.uchicago.edu/toc/jiden
dc.rightsArchived on this site with permission and copyright 200X by the Infectious Diseases Society of Americaen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAntimony Sodium Gluconateen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshDisease Outbreaksen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshGiardiasisen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshLeishmaniasis, Visceralen
dc.subject.meshMalariaen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshNutrition Disordersen
dc.subject.meshParomomycinen
dc.subject.meshPregnancyen
dc.subject.meshSudanen
dc.subject.meshWeight Lossen
dc.titleEpidemic Visceral Leishmaniasis in Sudan: A Randomized Trial of Aminosidine Plus Sodium Stibogluconate Versus Sodium Stibogluconate Alone.en
dc.contributor.departmentMedecins Sans Frontieres-Holland, Amsterdam.en
dc.identifier.journalThe Journal of Infectious Diseasesen
refterms.dateFOA2019-03-04T09:49:07Z
html.description.abstractIn a comparative trial of treatment in southern Sudan, visceral leishmaniasis was diagnosed by the following symptoms: fever for > 1 month, splenomegaly, and antileishmanial direct agglutination test (DAT) titer of > or = 1:25,600. Patients (200) were randomized to receive sodium stibogluconate (Sbv) at 20 mg/kg/day for 30 days (groups S, n = 99) or Sbv at 20 mg/kg/day plus aminosidine at 15 mg/kg/day for 17 days (group AS, n = 101). Of 192 patients who had spleens or lymph nodes aspirated at entry, 134 (70%) were positive for parasites. During treatment, 7% in group S and 4% in group AS died. All 184 patients who completed treatment were clinically cured. At days 15-17, microscopy of aspirates showed that 57 (95%) of 60 in group AS were negative for parasites compared with 47 (81%) of 58 in group S (P = .018). At day 30, 57 (93.4%) of 61 group S aspirates were negative.


Files in this item

Thumbnail
Name:
seaman.pdf
Size:
548.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record